HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lassmann, M. Articles by Reiners, C. Search for Related Content PubMed PubMed Citation Articles by Lassmann, M. Articles by Reiners, C.

Impact of ¹³¹I Diagnostic Activities on the Biokinetics of Thyroid Remnants

Klinik und Poliklinik für Nuklearmedizin der Universität Würzburg, Würzburg, Germany

Recent publications described many discrepant findings about thyroid "stunning" after the administration of ¹³¹I diagnostic activities to patients with differentiated thyroid carcinoma. Stunning may play a major role in reducing the therapeutic efficacy of high ¹³¹I activities given for ablation therapy. Methods: Participation in a multicenter study to investigate differences in iodine biokinetics in the hypothyroid state and after the application of recombinant human thyroid-stimulating hormone enabled us to study quantitative changes in thyroid iodine biokinetics after the administration of 74 MBq of ¹³¹I twice within 6 wk and an ablation activity of 3–4 GBq 7–12 d after the second diagnostic administration of ¹³¹I in 6 patients. Results: The uptake and half-life of the first 74 MBq of ¹³¹I were significantly reduced to a mean of 44% and a mean of 51%, respectively, after the second diagnostic administration and further reduced to a mean of 40% and a mean of 30%, respectively, during ablation therapy. The residence times were reduced to 25% in the second dosimetric assessment and to 10% during therapy compared with the value in the first assessment. For one patient, an estimated absorbed dose as high as 38 Gy was found in the first diagnostic study. The mean dose for all patients after the first assessment was 15 Gy; after each further assessment, the dose was reduced according to the decrease in residence time. Conclusion: This study shows a severe impact of 74 MBq of ¹³¹I on the biokinetics of thyroid remnants during subsequent radioiodine therapy.

Key Words: differentiated thyroid cancer • radioiodine therapy • recombinant human thyroid-stimulating hormone • dosimetry • stunning

This article has been cited by other articles:

				C. Lundh, M. M. Norden, M. Nilsson, and E. Forssell-Aronsson Reduced Iodide Transport (Stunning) and DNA Synthesis in Thyrocytes Exposed to Low Absorbed Doses from 131I In Vitro J. Nucl. Med., March 1, 2007; 48(3): 481 - 486. [Abstract] [Full Text] [PDF]

				R. B T Verkooijen, D. Rietbergen, J. W Smit, J. A Romijn, and M. P M Stokkel A new functional parameter measured at the time of ablation that can be used to predict differentiated thyroid cancer recurrence during follow-up Eur. J. Endocrinol., January 1, 2007; 156(1): 41 - 47. [Abstract] [Full Text] [PDF]

				J. C. Sisson, A. M. Avram, S. A. Lawson, P. G. Gauger, and G. M. Doherty The So-Called Stunning of Thyroid Tissue J. Nucl. Med., September 1, 2006; 47(9): 1406 - 1412. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J. W A Smit, W. Wiersinga, and the European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol., June 1, 2006; 154(6): 787 - 803. [Full Text] [PDF]

				F. Pacini, P. W. Ladenson, M. Schlumberger, A. Driedger, M. Luster, R. T. Kloos, S. Sherman, B. Haugen, C. Corone, E. Molinaro, et al. Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 926 - 932. [Abstract] [Full Text] [PDF]

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				S. K. Gerard and H. Q. Dam Stunning with 131I Diagnostic Whole-Body Imaging of Patients with Thyroid Cancer * Dr Dam responds: Radiology, March 1, 2005; 234(3): 972 - 974. [Full Text] [PDF]

				R. J. Robbins and M. J. Schlumberger The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 28S - 37S. [Abstract] [Full Text] [PDF]